NCT01374594

Brief Summary

PURPOSE The goal of the present project is to unravel the importance of bile acid-induced GLP-1 secretion (via the G protein-coupled receptor TGR5) in human physiology. In the present study the investigators examine the GLP-1 secretion in healthy subjects and in Type 2 Diabetes Mellitus (T2DM) patients. The investigators hypothesize that patients with T2DM of relatively long duration will be characterized by reduced gall bladder emptying, and, consequently, reduced intestinal TGR5 activation; resulting in attenuated postprandial GLP-1 responses (primary endpoint).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

June 14, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 16, 2011

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2012

Completed
Last Updated

January 23, 2013

Status Verified

January 1, 2013

Enrollment Period

1 year

First QC Date

June 14, 2011

Last Update Submit

January 22, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • GLP-1 secretion

    Postprandial

Study Arms (2)

Healthy adults

Type 2 diabetes

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy subjects and type 2 diabetes patients (T2DM)

You may qualify if:

  • HbA1 \< 6 %
  • Normal haemoglobin levels
  • Informed content
  • T2DM \> 5 years
  • Normal haemoglobin levels
  • Informed content

You may not qualify if:

  • Treatment with insulin, DPP-IV inhibitor or GLP-1 analogues
  • Obesity (BMI \> 30)
  • Age \> 70 years
  • Gastrointestinal disease
  • Nephropathy
  • Liver disease
  • Medication which cannot be on hold for 12h
  • Gastrointestinal surgery
  • st degree relatives with diabetes
  • Obesity (BMI \> 30)
  • Age \> 70 years
  • Gastrointestinal disease
  • Nephropathy
  • Liver disease
  • Medication which cannot be on hold for 12h
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gentofte University Hospital

Hellerup, 2900, Denmark

Location

Related Publications (2)

  • Sonne DP, van Nierop FS, Kulik W, Soeters MR, Vilsboll T, Knop FK. Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Aug;101(8):3002-9. doi: 10.1210/jc.2016-1607. Epub 2016 Jun 7.

  • Sonne DP, Vilsboll T, Knop FK. Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. Diabetes Care. 2015 May;38(5):e71-2. doi: 10.2337/dc14-2751. No abstract available.

Biospecimen

blood samples

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

June 14, 2011

First Posted

June 16, 2011

Study Start

June 1, 2011

Primary Completion

June 1, 2012

Study Completion

November 1, 2012

Last Updated

January 23, 2013

Record last verified: 2013-01

Locations